ETF Holdings Breakdown of GMAB

GMAB institutional holdings

The adjusted close for GMAB on 2025-11-11 was 30.31

The following institutional investment holdings of GMAB have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	26,909	USD 815,612	30.31
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	26,909	USD 815,612 4.1%	30.31
Total =		53,818	USD 1,631,224

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with GMAB

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating […] - 2025-08-27 02:38:58

Genmab A/S (NASDAQ:GMAB) Price Target Raised to $36.00

Genmab A/S (NASDAQ:GMAB – Free Report) had its target price lifted by HC Wainwright from $35.00 to $36.00 in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q1 2026 earnings at $0.34 EPS, Q2 2026 […] - 2025-08-18 03:01:11

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Headlands Technologies LLC

Headlands Technologies LLC increased its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 1,525.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,560 shares of the company’s stock after purchasing an additional 1,464 shares during the period. […] - 2025-08-14 04:45:19

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Sold by US Bancorp DE

US Bancorp DE lessened its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 34.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 107,553 shares of the company’s stock after selling 56,995 shares during the period. US Bancorp DE’s […] - 2025-08-08 06:22:50

Natixis Advisors LLC Decreases Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Natixis Advisors LLC decreased its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 37.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,525 shares of the company’s stock after selling 77,244 shares during the quarter. Natixis Advisors LLC’s […] - 2025-08-08 05:24:58

Genmab's Epcoritamab Combo Shows Strong Results In Follicular Lymphoma Trial

(RTTNews) - Genmab A/S (GMAB), Thursday announced positive results from its Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma. - 2025-08-07 12:34:08

XTX Topco Ltd Acquires Shares of 30,929 Genmab A/S Sponsored ADR (NASDAQ:GMAB)

XTX Topco Ltd acquired a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 30,929 shares of the company’s stock, valued at approximately $606,000. Other hedge funds and other institutional investors also recently modified their […] - 2025-08-06 05:20:51

Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $37.80

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation […] - 2025-08-05 02:55:11

Choreo LLC Grows Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Choreo LLC raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 19.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 26,040 shares of the company’s stock after purchasing an additional 4,226 shares during the period. Choreo LLC’s holdings in Genmab A/S […] - 2025-07-28 04:38:57

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Sold by Cerity Partners LLC

Cerity Partners LLC decreased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 20.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 40,904 shares of the company’s stock after selling 10,360 shares during the period. Cerity Partners LLC’s holdings in Genmab A/S were worth $801,000 at the end of the […] - 2025-07-24 04:34:54

Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Wall Street Zen

Genmab A/S (NASDAQ:GMAB – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. A number of other analysts have also commented on GMAB. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price […] - 2025-07-14 03:54:44

Truist Financial Forecasts Strong Price Appreciation for Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S (NASDAQ:GMAB – Free Report) had its target price increased by Truist Financial from $45.00 to $46.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several other analysts also recently weighed in on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a “market […] - 2025-07-11 04:34:48

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have given a buy recommendation and one has […] - 2025-07-08 03:12:51

Blue Trust Inc. Raises Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Blue Trust Inc. increased its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 169.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 7,413 shares of the company’s stock after purchasing an additional 4,666 shares during the period. Blue Trust Inc.’s holdings […] - 2025-06-25 04:36:54

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by QRG Capital Management Inc.

QRG Capital Management Inc. increased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 213.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,847 shares of the company’s stock after purchasing an additional 50,990 shares during the quarter. QRG Capital Management […] - 2025-06-20 05:38:52

Genmab A/S (NASDAQ:GMAB) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its position in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 1,235.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,507 shares of the company’s stock after acquiring an additional 108,705 shares during the quarter. Squarepoint Ops […] - 2025-05-28 05:30:52

Dimensional Fund Advisors LP Sells 24,894 Shares of Genmab A/S (NASDAQ:GMAB)

Dimensional Fund Advisors LP reduced its holdings in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 35.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 45,615 shares of the company’s stock after selling 24,894 shares during the period. Dimensional Fund Advisors LP’s holdings in Genmab A/S were worth $952,000 at the […] - 2025-05-16 04:50:56

Mercer Global Advisors Inc. ADV Trims Stock Position in Genmab A/S (NASDAQ:GMAB)

Mercer Global Advisors Inc. ADV reduced its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,843 shares of the company’s stock after selling 4,804 shares during the quarter. Mercer […] - 2025-05-14 05:34:56

CANADA LIFE ASSURANCE Co Sells 1,143 Shares of Genmab A/S (NASDAQ:GMAB)

CANADA LIFE ASSURANCE Co lowered its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 42.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,567 shares of the company’s stock after selling 1,143 shares during the quarter. CANADA LIFE ASSURANCE […] - 2025-05-01 05:50:46

Bank of Montreal Can Has $670,000 Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Bank of Montreal Can decreased its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 57.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,109 shares of the company’s stock after selling 43,710 shares during the quarter. Bank of Montreal Can’s holdings in Genmab […] - 2025-04-21 04:38:47

Envestnet Asset Management Inc. Has $15.11 Million Holdings in Genmab A/S (NASDAQ:GMAB)

Envestnet Asset Management Inc. decreased its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 30.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 723,781 shares of the company’s stock after selling 319,779 shares during the quarter. Envestnet Asset Management Inc. owned […] - 2025-04-16 05:05:01

Genmab A/S (NASDAQ:GMAB) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC lessened its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 18.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,376 shares of the company’s stock after selling 3,919 shares during the quarter. Orion Portfolio Solutions LLC’s […] - 2025-04-09 05:02:51

Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Sanford C. Bernstein

Genmab A/S (NASDAQ:GMAB – Get Free Report) was downgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. GMAB has been the subject of several other reports. Truist Financial reduced their price objective on Genmab A/S […] - 2025-04-03 04:41:01

Genmab A/S (NASDAQ:GMAB) Receives $41.33 Consensus PT from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have been given an average rating of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and […] - 2025-04-02 02:51:03

Genmab A/S (NASDAQ:GMAB) Holdings Decreased by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,077 shares of the company’s stock after selling 8,330 shares during the period. Envestnet Portfolio […] - 2025-03-27 06:43:00

Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 18,109 shares of the company’s stock after selling 64,520 shares during the quarter. Assetmark Inc.’s holdings in Genmab A/S were worth $378,000 at the end of the most recent quarter. Other […] - 2025-03-13 06:37:04

Genmab A/S (NASDAQ:GMAB) Raised to Outperform at William Blair

Genmab A/S (NASDAQ:GMAB – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a note issued to investors on Tuesday, Marketbeat reports. William Blair also issued estimates for Genmab A/S’s FY2028 earnings at $4.06 EPS. A number of other brokerages have also weighed in on GMAB. […] - 2025-03-13 04:18:47

Genmab A/S (NASDAQ:GMAB) Stock Holdings Trimmed by QRG Capital Management Inc.

QRG Capital Management Inc. lowered its holdings in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 19.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,857 shares of the company’s stock after selling 5,579 shares during the period. QRG Capital […] - 2025-03-06 09:19:40

Blue Trust Inc. Grows Stock Position in Genmab A/S (NASDAQ:GMAB)

Blue Trust Inc. grew its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 33.4% during the fourth quarter, HoldingsChannel reports. The fund owned 5,757 shares of the company’s stock after purchasing an additional 1,442 shares during the period. Blue Trust Inc.’s holdings in Genmab A/S were worth $120,000 as of its most recent SEC […] - 2025-02-07 07:38:11

Blue Trust Inc. Grows Stock Position in Genmab A/S (NASDAQ:GMAB)

Blue Trust Inc. grew its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 33.4% during the fourth quarter, HoldingsChannel reports. The fund owned 5,757 shares of the company’s stock after purchasing an additional 1,442 shares during the period. Blue Trust Inc.’s holdings in Genmab A/S were worth $120,000 as of its most recent SEC […] - 2025-02-07 06:32:57

Back to Listing

Disclaimer